Trial Profile
Anlotinib Combined With Docetaxel Versus Docetaxel for Platinum-based Therapy Treated Advanced NSCLC: a Multicentre, Randomised Explorative Trial
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Docetaxel
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ACWDVDFPTAN; ALTER-L016
- 13 Sep 2022 Updated results presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Results of pooled analysis of two studies (ALTER-L016: NCT03726736; ALTER-L018: NCT03624309) assessing efficacy and safety anlotinib plus docetaxel in the treatment of non-small cell lung cancer, presented at the 47th European Society for Medical Oncology Congress.
- 09 Aug 2022 Results of pooled analysis (n=73) assessing the efficacy and safety of anlotinib plus docetaxel in advanced NSCLC patients (pts) who had been pre-treated with ICIs presented at the 2022 World Conference on Lung Cancer